Akari Therapeutics Plc Stock Alpha and Beta Analysis
| AKTX Stock | USD 0.87 0.03 3.33% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Akari Therapeutics PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Akari Therapeutics over a specified time horizon. Remember, high Akari Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Akari Therapeutics' market risk premium analysis include:
Beta 0.82 | Alpha (0.27) | Risk 6.57 | Sharpe Ratio (0.08) | Expected Return (0.53) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Akari |
Akari Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Akari Therapeutics market risk premium is the additional return an investor will receive from holding Akari Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Akari Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Akari Therapeutics' performance over market.| α | -0.27 | β | 0.82 |
Akari Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Akari Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Akari Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Akari Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Akari Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Akari Therapeutics shares will generate the highest return on investment. By understating and applying Akari Therapeutics stock market price indicators, traders can identify Akari Therapeutics position entry and exit signals to maximize returns.
Akari Therapeutics Return and Market Media
The median price of Akari Therapeutics for the period between Sun, Dec 1, 2024 and Sat, Mar 1, 2025 is 1.16 with a coefficient of variation of 12.54. The daily time series for the period is distributed with a sample standard deviation of 0.14, arithmetic mean of 1.14, and mean deviation of 0.12. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Patel Samir Rashmikant of 162604000 shares of Akari Therapeutics at 6.0E-4 subject to Rule 16b-3 | 11/29/2024 |
2 | Acquisition by Prudo-chlebosz Raymond of 419286000 shares of Akari Therapeutics at 0.0011 subject to Rule 16b-3 | 12/02/2024 |
3 | Akari Therapeutics Coverage Initiated by Analysts at StockNews.com | 12/06/2024 |
4 | Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer | 12/16/2024 |
5 | Acquisition by Patel Samir Rashmikant of 1400000 shares of Akari Therapeutics at 5.0E-4 subject to Rule 16b-3 | 12/20/2024 |
6 | Acquisition by Patel Samir Rashmikant of 7500000 shares of Akari Therapeutics at 5.0E-4 subject to Rule 16b-3 | 12/24/2024 |
7 | Acquisition by Gaslightwala Abizer of 40000000 shares of Akari Therapeutics at 5.0E-4 subject to Rule 16b-3 | 12/27/2024 |
8 | Acquisition by Patel Samir Rashmikant of 152672000 shares of Akari Therapeutics at 6.0E-4 subject to Rule 16b-3 | 01/03/2025 |
9 | Insider Trading | 01/08/2025 |
10 | Acquisition by Torsten Hombeck of 200 shares of Akari Therapeutics at 1.22 subject to Rule 16b-3 | 01/10/2025 |
11 | Akari Therapeutics Share Price Passes Above 50 Day Moving Average Heres What Happened | 01/29/2025 |
12 | Disposition of 1300000 shares by Williams Donald A of Akari Therapeutics at 0.0218 subject to Rule 16b-3 | 02/14/2025 |
13 | Akari Therapeutics Participates in the Virtual Investor Top 5 for 25 On-Demand Conference | 02/19/2025 |
About Akari Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Akari or other stocks. Alpha measures the amount that position in Akari Therapeutics PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Net Debt To EBITDA | 0.57 | 0.26 | 0.25 | Intangibles To Total Assets | 0.00122 | 0.002893 | 0.003038 |
Akari Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Akari Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akari Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Akari Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Akari Therapeutics. Please utilize our Beneish M Score to check the likelihood of Akari Therapeutics' management manipulating its earnings.
| 6th of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Akari Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.